The present invention relates generally to the field of apparatuses and methods for ablating or coagulating the interior surfaces of body organs. Specifically, it relates to an apparatus and method for ablating the interior linings of body organs such as the uterus and gallbladder.
Ablation of the interior lining of a body organ is a procedure which involves heating the organ lining to temperatures which destroy the cells of the lining or coagulate tissue proteins for hemostasis. Such a procedure may be performed as a treatment to one of many conditions, such as chronic bleeding of the endometrial layer of the uterus or abnormalities of the mucosal layer of the gallbladder. Existing methods for effecting ablation include circulation of heated fluid inside the organ (either directly or inside a balloon), laser treatment of the organ lining, and resistive heating using application of RF energy to the tissue to be ablated.
U.S. Pat. No. 5,084,044 describes an apparatus for endometrial ablation in which a bladder is inserted into the uterus. Heated fluid is then circulated through the balloon to expand the balloon into contact with the endometrium and to ablate the endometrium thermally. U.S. Pat. No. 5,443,470 describes an apparatus for endometrial ablation in which an expandable bladder is provided with electrodes on its outer surface. After the apparatus is positioned inside the uterus, a non-conductive gas or liquid is used to fill the balloon, causing the balloon to push the electrodes into contact with the endometrial surface. RF energy is supplied to the electrodes to ablate the endometrial tissue using resistive heating.
These ablation devices are satisfactory for carrying out ablation procedures. However, because no data or feedback is available to guide the physician as to how deep the tissue ablation has progressed, controlling the ablation depth and ablation profile with such devices can only be done by assumption.
For example, the heated fluid method is a very passive and ineffective heating process which relies on the heat conductivity of the tissue. This process does not account for variations in factors such as the amount of contact between the balloon and the underlying tissue, or cooling effects such as those of blood circulating through the organ. RF ablation techniques can achieve more effective ablation since it relies on active heating of the tissue using RF energy, but presently the depth of ablation using RF techniques can only be estimated by the physician since no feedback can be provided as to actual ablation depth.
Both the heated fluid techniques and the latest RF techniques must be performed using great care to prevent over ablation. Monitoring of tissue surface temperature is normally carried out during these ablation procedures to ensure the temperature does not exceed 100° C. If the temperature exceeds 100° C., the fluid within the tissue begins to boil and to thereby produce steam. Because ablation is carried out within a closed cavity within the body, the steam cannot escape and may instead force itself deeply into the tissue, or it may pass into areas adjacent to the area intended to be ablated, causing embolism or unintended burning.
Moreover, in prior art RF devices the water drawn from the tissue creates a path of conductivity through which current traveling through the electrodes will flow. This can prevent the current from traveling into the tissue to be ablated. Moreover, the presence of this current path around the electrodes causes current to be continuously drawn from the electrodes. The current heats the liquid drawn from the tissue and thus turns the ablation process into a passive heating method in which the heated liquid around the electrodes causes thermal ablation to continue well beyond the desired ablation depths.
Another problem with prior art ablation devices is that it is difficult for a physician to find out when ablation has been carried out to a desired depth within the tissue. Thus, it is often the case that too much or too little tissue may be ablated during an ablation procedure.
It is therefore desirable to provide an ablation device which eliminates the above-described problem of steam and liquid buildup at the ablation site. It is further desirable to provide an ablation method and device which allows the depth of ablation to be controlled and which automatically discontinues ablation once the desired ablation depth has been reached.
The present invention is an apparatus and method of ablating and/or coagulating tissue, such as that of the uterus or other organ. An ablation device is provided which has an electrode array carried by an elongate tubular member. The electrode array includes a fluid permeable elastic member preferably formed of a metallized fabric having insulating regions and conductive regions thereon. During use, the electrode array is positioned in contact with tissue to be ablated, ablation energy is delivered through the array to the tissue to cause the tissue to dehydrate, and moisture generated during dehydration is actively or passively drawn into the array and away from the tissue.
The invention described in this application is an aspect of a larger set of inventions described in the following co-pending applications which are commonly owned by the assignee of the present invention, and are hereby incorporated by reference: U.S. Provisional Patent Application No. 60/084,724, filed May 8, 1998, entitled “APPARATUS AND METHOD FOR INTRA-ORGAN MEASUREMENT AND ABLATION”; and U.S. Provisional Patent Application No. 60/084,712.
The ablation apparatus according to the present invention will be described with respect to two exemplary embodiments.
Referring to
Shaft 10 is an elongate member having a hollow interior. Shaft 10 is preferably 12 inches long and has a preferred cross-sectional diameter of approximately 4 mm. A collar 13 is formed on the exterior of the shaft 10 at the proximal end. As best shown in
Extending through the shaft 10 is a suction/insufflation tube 17 (
Referring to
Electrically insulated sensor leads 23a, 23b (
Referring to
Referring to
The electrode carrying means 12 preferably has a shape which approximates the shape of the body organ which is to be ablated. For example, the apparatus shown in
Electrode carrying means 12 is preferably a sack formed of a material which is non-conductive, which is permeable to moisture and/or which has a tendency to absorb moisture, and which may be compressed to a smaller volume and subsequently released to its natural size upon elimination of compression. Examples of preferred materials for the electrode carrying means include open cell sponge, foam, cotton, fabric, or cotton-like material, or any other material having the desired characteristics. Alternatively, the electrode carrying means may be formed of a metallized fabric. For convenience, the term “pad” may be used interchangeably with the term electrode carrying means to refer to an electrode carrying means formed of any of the above materials or having the listed properties.
Electrodes 14 are preferably attached to the outer surface of the electrode carrying means 12, such as by deposition or other attachment mechanism. The electrodes are preferably made of lengths of silver, gold, platinum, or any other conductive material. The electrodes may be attached to the electrode carrying means 12 by electron beam deposition, or they may be formed into coiled wires and bonded to the electrode carrying member using a flexible adhesive. Naturally, other means of attaching the electrodes, such as sewing them onto the surface of the carrying member, may alternatively be used. If the electrode carrying means 12 is formed of a metallized fabric, an insulating layer may be etched onto the fabric surface, leaving only the electrode regions exposed.
The spacing between the electrodes (i.e. the distance between the centers of adjacent electrodes) and the widths of the electrodes are selected so that ablation will reach predetermined depths within the tissue, particularly when maximum power is delivered through the electrodes (where maximum power is the level at which low impedance, low voltage ablation can be achieved).
The depth of ablation is also effected by the electrode density (i.e., the percentage of the target tissue area which is in contact with active electrode surfaces) and may be regulated by pre-selecting the amount of this active electrode coverage. For example, the depth of ablation is much greater when the active electrode surface covers more than 10% of the target tissue than it is when the active electrode surfaces covers 1% of the target tissue.
For example, by using 3-6 mm spacing and an electrode width of approximately 0.5-2.5 mm, delivery of approximately 20-40 watts over a 9-16 cm2 target tissue area will cause ablation to a depth of approximately 5-7 millimeters when the active electrode surface covers more than 10% of the target tissue area. After reaching this ablation depth, the impedance of the tissue will become so great that ablation will self-terminate as described with respect to the operation of the invention.
By contrast, using the same power, spacing, electrode width, and RF frequency will produce an ablation depth of only 2-3 mm when the active electrode surfaces covers less than 1% of the target tissue area. This can be better understood with reference to
As is apparent from
Some examples of electrode widths, having spacings with more than 10% active electrode surface coverage, and their resultant ablation depth, based on an ablation area of 6 cm2 and a power of 20-40 watts, are given on the following table:
Examples of electrode widths, having spacings with less than 1% active electrode surface coverage, and their resultant ablation depth, based on an ablation area of 6 cm2 and a power of 20-40 watts, are given on the following table:
Thus it can be seen that the depth of ablation is significantly less when the active electrode surface coverage is decreased.
In the preferred embodiment, the preferred electrode spacing is approximately 8-10 mm in the horn regions 26 with the active electrode surfaces covering approximately 1% of the target region. Approximately 1-2 mm electrode spacing (with 10% active electrode coverage) is preferred in the cervical region (designated 28) and approximately 3-6 mm (with greater than 10% active electrode surface coverage) is preferred in the main body region.
The RF generator 16 may be configured to include a controller which gives the user a choice of which electrodes should be energized during a particular application in order to give the user control of ablation depth. For example, during an application for which deep ablation is desired, the user may elect to have the generator energize every other electrode, to thereby optimize the effective spacing of the electrodes and to decrease the percentage of active electrode surface coverage, as will be described below with respect to
Although the electrodes shown in the drawings are arranged in a particular pattern, it should be appreciated that the electrodes may be arranged in any pattern to provide ablation to desired depths.
Referring to
A handle 34 attached to the sheath 32 provides finger holds to allow for manipulation of the sheath 32. Handle 34 is slidably mounted on a handle rail 35 which includes a sleeve 33, a finger cutout 37, and a pair of spaced rails 35a, 35b extending between the sleeve 33 and the finger cutout 37. The shaft 10 and sheath 32 slidably extend through the sleeve 33 and between the rails 35a, 35b. The tube 17 also extends through the sleeve 33 and between the rails 35a, 35b, and its proximal end is fixed to the handle rail 35 near the finger cutout 37.
A compression spring 39 is disposed around the proximal most portion of the suction/insufflation tube 17 which lies between the rails 35a, 35b. One end of the compression spring 39 rests against the collar 13 on the shaft 10, while the opposite end of the compression spring rests against the handle rail 35. During use, the sheath 32 is retracted from the electrode carrying means 12 by squeezing the handle 34 towards the finger cutout 37 to slide the sheath 32 in the distal direction. When the handle 34 advances against the collar 13, the shaft 10 (which is attached to the collar 13) is forced to slide in the proximal direction, causing compression of the spring 39 against the handle rail 35. The movement of the shaft 10 relative to the suction/insufflation tube 17 causes the shaft 10 to pull proximally on the passive spring member 15. Proximal movement of the passive spring member 15 in turn pulls against the active spring member 19, causing it to move to the opened condition shown in
The amount by which the springs 15, 19 are spread may be controlled by manipulating the handle 34 to slide the shaft 10 (via collar 13), proximally or distally. Such sliding movement of the shaft 10 causes forceps-like movement of the spring members 15, 19.
A flow pathway 36 is formed in the handle rail 35 and is fluidly coupled to a suction/insufflation port 38. The proximal end of the suction/insufflation tube 17 is fluidly coupled to the flow pathway so that gas fluid may be introduced into, or withdrawn from the suction/insufflation tube 17 via the suction/insufflation port 38. For example, suction may be applied to the fluid port 38 using a suction/insufflation unit 40. This causes water vapor within the uterine cavity to pass through the permeable electrode carrying means 12, into the suction/insufflation tube 17 via holes 17a, through the tube 17, and through the suction/insufflation unit 40 via the port 38. If insufflation of the uterine cavity is desired, insufflation gas, such as carbon dioxide, may be introduced into the suction/insufflation tube 17 via the port 38. The insufflation gas travels through the tube 17, through the holes 17a, and into the uterine cavity through the permeable electrode carrying member 12.
If desirable, additional components may be provided for endoscopic visualization purposes. For example, lumen 42, 44, and 46 may be formed in the walls of the introducer sheath 32 as shown in
Because during use it is most desirable for the electrodes 14 on the surface of the electrode carrying means 12 to be held in contact with the interior surface of the organ to be ablated, the electrode carrying means 12 may be provided to have additional components inside it that add structural integrity to the electrode carrying means when it is deployed within the body.
For example, referring to
Alternatively, a pair of inflatable balloons 52 may be arranged inside the electrode carrying means 12 as shown in
Structural integrity may also be added to the electrode carrying means through the application of suction to the proximal end 22a of the suction/insufflation tube 17. Application of suction using the suction/insufflation device 40 would draw the organ tissue towards the electrode carrying means 12 and thus into better contact with the electrodes 14.
Operation of the first exemplary embodiment of an ablation device according to the present invention will next be described.
Referring to
At this time, the electrical connector 21 is connected to the RF generator 16, and the fiberoptic cable 48 and the illumination cable 50 are connected to the illumination source, monitor, and camera, 54, 56, 45. The suction/insufflation unit 40 is attached to suction/insufflation port 38 on the handle rail 35. The suction/insufflation unit 40 is preferably set to deliver carbon dioxide at an insufflation pressure of 20-200 mmHg.
Next, the distal end of the apparatus is inserted through the vaginal opening V and into the uterus U as shown in
Following insertion, the handle 34 is withdrawn until it abuts the collar 13. At this point, the sheath 32 exposes the electrode carrying member 12 but the electrode carrying member 12 is not yet fully expanded (see
The physician may confirm proper positioning of the electrode carrying member 12 using the monitor 56, which displays images from the fiberoptic cable 48.
Proper positioning of the device and sufficient contact between the electrode carrying member 12 and the endometrium may further be confirmed using the contact sensors 25a, 25b. The monitoring module of the RF generator measures the impedance between these sensors using conventional means. If there is good contact between the sensors and the endometrium, the measured impedance will be approximately 20-180 ohm, depending on the water content of the endometrial lining.
The sensors are positioned on the distal portions of the bicornual shaped electrode carrying member 12, which during use are positioned in the regions within the uterus in which it is most difficult to achieve good contact with the endometrium. Thus, an indication from the sensors 25a, 25b that there is sound contact between the sensors and the endometrial surface indicates that good electrode contact has been made with the endometrium.
Next, insufflation is terminated. Approximately 1-5 cc of saline may be introduced via suction/insufflation tube 17 to initially wet the electrodes and to improve electrode electrical contact with the tissue. After introduction of saline, the suction/insufflation device 40 is switched to a suctioning mode. As described above, the application of suction to the RF applicator head 2 via the suction/insufflation tube 17 collapses the uterine cavity onto the RF applicator head 2 and thus assures better contact between the electrodes and the endometrial tissue.
If the generally tubular apparatus of
Next, RF energy at preferably about 500 kHz and at a constant power of approximately 30 W is applied to the electrodes. As shown in
Moreover, ablation depth may be controlled as described above by providing low surface density electrodes on areas of the electrode carrying member which will contact tissue areas at which a smaller ablation depth is required (see
As another example, shown in
As the endometrial tissue heats, moisture begins to be released from the tissue. The moisture permeates the electrode carrying member 12 and is thereby drawn away from the electrodes. The moisture may pass through the holes 17a in the suction/insufflation tube 17 and leave the suction/insufflation tube 17 at its proximal end via port 38 as shown in
Removal of the moisture from the ablation site prevents formation of a liquid layer around the electrodes. As described above, liquid build-up at the ablation site is detrimental in that provides a conductive layer that carries current from the electrodes even when ablation has reached the desired depth. This continued current flow heats the liquid and surrounding tissue, and thus causes ablation to continue by unpredictable thermal conduction means.
Tissue which has been ablated becomes dehydrated and thus decreases in conductivity. By shunting moisture away from the ablation site and thus preventing liquid build-up, there is no liquid conductor at the ablation area during use of the ablation device of the present invention. Thus, when ablation has reached the desired depth, the impedance at the tissue surface becomes sufficiently high to stop or nearly stop the flow of current into the tissue. RF ablation thereby stops and thermal ablation does not occur in significant amounts. If the RF generator is equipped with an impedance monitor, a physician utilizing the ablation device can monitor the impedance at the electrodes and will know that ablation has self-terminated once the impedance rises to a certain level and then remains fairly constant. By contrast, if a prior art bipolar RF ablation device was used together with an impedance monitor, the presence of liquid around the electrodes would cause the impedance monitor to give a low impedance reading regardless of the depth of ablation which had already been carried out, since current would continue to travel through the low-impedance liquid layer.
Other means for monitoring and terminating ablation may also be provided. For example, a thermocouple or other temperature sensor may be inserted to a predetermined depth in the tissue to monitor the temperature of the tissue and terminate the delivery of RF energy or otherwise signal the user when the tissue has reached a desired ablation temperature.
Once the process has self terminated, 1-5 cc of saline can be introduced via suction/insufflation tube 17 and allowed to sit for a short time to aid separation of the electrode from the tissue surface. The suction insufflation device 40 is then switched to provide insufflation of carbon dioxide at a pressure of 20-200 mmHg. The insufflation pressure helps to lift the ablated tissue away from the RF applicator head 2 and to thus ease the closing of the RF applicator head. The RF applicator head 2 is moved to the closed position by sliding the handle 34 in a distal direction to fold the spring members 15, 19 along the axis of the device and to cause the introducer sheath 32 to slide over the folded RF applicator head. The physician may visually confirm the sufficiency of the ablation using the monitor 56. Finally, the apparatus is removed from the uterine cavity.
A second embodiment of an ablation device 100 in accordance with the present invention is shown in
Referring to
RF Applicator Head
Referring to
Referring to
This knit of elastic (spandex) and inelastic (nylon) yarns is beneficial for a number of reasons. For example, knitting elastic and relatively inelastic yarns allows the overall deformability of the array to be pre-selected.
The mesh is preferably constructed so as to have greater elasticity in the transverse direction (T) than in the longitudinal direction (L). In a preferred mesh design, the transverse elasticity is on the order of approximately 300% whereas the longitudinal elasticity is on the order of approximately 100%. The large transverse elasticity of the array allows it to be used in a wide range of uterine sizes.
Another advantage provided by the combination of elastic and relatively inelastic yarns is that the elastic yarns provide the needed elasticity to the array while the relatively inelastic yarns provide relatively non-stretchable members to which the metallization can adhere without cracking during expansion of the array. In the knit configuration described above, the metallization adheres to the nylon coiled around the spandex. During expansion of the array, the spandex elongates and the nylon double helix at least partially elongates from its coiled configuration.
One process which may be used to apply the gold to the nylon/spandex knit involves plating the knit with silver using known processes which involve application of other materials as base layers prior to application of the silver to ensure that the silver will adhere. Next, the insulating regions 110 (described below) are etched onto the silver, and afterwards the gold is plated onto the silver. Gold is desirable for the array because of it has a relatively smooth surface, is a very inert material, and has sufficient ductility that it will not crack as the nylon coil elongates during use.
The mesh may be configured in a variety of shapes, including but not limited to the triangular shape S1, parabolic S2, and rectangular S3 shapes shown in
Turning again to
Insulating regions 110 are formed on the applicator head to divide the mesh into electrode regions. The insulated regions 110 are preferably formed using etching techniques to remove the conductive metal from the mesh, although alternate methods may also be used, such as by knitting conductive and non-conductive materials together to form the array.
The array may be divided by the insulated regions 110 into a variety of electrode configurations. In a preferred configuration the insulating regions 110 divide the applicator head into four electrodes 118a-118d by creating two electrodes on each of the broad faces 112. To create this four-electrode pattern, insulating regions 110 are placed longitudinally along each of the broad faces 112 as well as along the length of each of the faces 114, 116. The electrodes 118a-118d are used for ablation and, if desired, to measure tissue impedance during use.
Deflecting mechanism 102b and its deployment structure is enclosed within electrode array 102a. Referring to
Each flexure 124 preferably includes conductive regions that are electrically coupled to the array 102a for delivery of RF energy to the body tissue. Referring to
During use, one strip 128 on each conductor is electrically coupled via the conductor leads to one terminal on the RF generator while the other strip is electrically coupled to the opposite terminal, thus causing the array on the applicator head to have regions of alternating positive and negative polarity.
The flexures may alternatively be formed using a conductive material or a conductively coated material having insulating regions formed thereon to divide the flexure surfaces into multiple conductive regions. Moreover, alternative methods such as electrode leads independent of the flexures 124 may instead be used for electrically connecting the electrode array to the source of RF energy.
It is important to ensure proper alignment between the conductive regions of the flexures 124 (e.g. copper strips 128) and the electrodes 118a-118d in order to maintain electrical contact between the two. Strands of thread 134 (which may be nylon) (
Referring again to
The deflecting mechanism is preferably configured such that the distal tips of the flexures 124 are sufficiently flexible to prevent tissue puncture during deployment and/or use. Such an atraumatic tip design may be carried out in a number of ways, such as by manufacturing the distal sections 124a (
Alternatively, referring to
The deflecting mechanism formed by the flexures 124, 136, and ribbon 138 forms the array into the substantially triangular shape shown in
Measurement Device
The ablation device according to the second embodiment includes a measurement device for easily measuring the uterine width and for displaying the measured width on a gauge 146 (
Referring to
Expansion of the applicator head 102 during use pulls threads 148 (
The uterine width and length (as determined using a conventional sound or other means) are preferably input into an RF generator system and used by the system to calculate an appropriate ablation power as will be described below. Alternately, the width as measured by the apparatus of the invention and length as measured by other means may be used by the user to calculate the power to be supplied to the array to achieve the desired ablation depth.
The uterine width may alternatively be measured using other means, including by using a strain gauge in combination with an A/D converter to transduce the separation distance of the flexures 124 and to electronically transmit the uterine width to the RF generator.
Control of Ablation Depth
The most optimal electrocoagulation occurs when relatively deep ablation is carried out in the regions of the uterus at which the endometrium is thickest, and when relatively shallower ablation is carried out in areas in which the endometrium is shallower. A desirable range of ablation depths includes approximately 2-3 mm for the cervical os and the cornual regions, and approximately 7-8 mm in the main body of the uterus where the endometrium is substantially thicker.
As discussed with respect to the first embodiment, a number of factors influence the ablation depth that can be achieved using a given power applied to a bipolar electrode array. These include the power supplied by the RF generator, the distance between the centers of adjacent electrodes (“center-to-center distance”), the electrode density (i.e., the porosity of the array fabric or the percent of the array surface that is metallic), the edge gap (i.e. the distance between the edges of adjacent electrode poles), and the electrode surface area. Other factors include blood flow (which in slower-ablating systems can dissipate the RF) and the impedance limit.
Certain of these factors may be utilized in the present invention to control ablation depth and to provide deeper ablation at areas requiring deeper ablation and to provide shallower regions in areas where deep ablation is not needed. For example, as center-to-center distance increases, the depth of ablation increases until a point where the center to center distance is so great that the strength of the RF field is too diffuse to excite the tissue. It can been seen with reference to
Naturally, because the array 102a expands to accommodate the size of the uterus in which it is deployed, the dimensions of the array 102a vary. One embodiment of the array 102a includes a range of widths of at least approximately 2.5-4.5 cm, a range of lengths of at least approximately 4-6 cm, and a density of approximately 35%-45%.
The power supplied to the array by the RF generator is calculated by the RF generator system to accommodate the electrode area required for a particular patient. As discussed above, the uterine width is measured by the applicator head 102 and displayed on gauge 146. The uterine length is measured using a sound, which is an instrument conventionally used for that purpose. It should be noted that calibration markings of the type used on a conventional sound device, or other structure for length measurement, may be included on the present invention to allow it to be used for length measurement as well.
The user enters the measured dimensions into the RF generator system using an input device, and the RF generator system calculates or obtains the appropriate set power from a stored look-up table using the uterine width and length as entered by the user. An EPROM within the RF generator system converts the length and width to a set power level according to the following relationship:
P=L×W×5.5
Where P is the power level in watts, L is the length in centimeters, W is the width in centimeters, and 5.5 is a constant having units of watts per square centimeter.
Alternatively, the user may manually calculate the power setting from the length and width, or s/he may be provided with a table of suggested power settings for various electrode areas (as determined by the measured length and width) and will manually set the power on the RF generator accordingly.
Handle
Referring again to
The proximal grip section 144 is coupled to the hypotube 122 (
Referring to
A sliding collar 184 is slidably disposed on the tubing 108 and is slidable over male coupler 174. Sliding collar 184 includes a rotating collar 186 and a female coupler 176 that includes a wedge-shaped heel 188. A locking spring member 190 (
A release lever 194 (
Referring again to
Once the uterine length has been measured using a conventional sound, the user positions sliding collar 184 adjacent to calibration marks 182 corresponding to the measured uterine length (e.g. 4.5 cm). Afterwards, the user rotates the collar section 186 to engage its internally positioned teeth with the rack 180. This locks the longitudinal position of the heel 188 such that it will engage with the spring member 190 on the proximal grip when the array has been exposed to the length set by the sliding collar.
The handle 106 includes a pair of spring assemblies which facilitate controlled deployment and stowage of the array 102a. One of the spring assemblies controls movement of the grips 142, 144 to automatically stow the array 102a into the sheath 104 when the user stops squeezing the grips 142, 144 towards one another. The other of the spring assemblies controls the transverse movement of the spring flexures 124 to the expanded condition by limiting the maximum load that can be applied to the deployment mechanism 102b.
The lowermost end of the return mandrel 196 is pivotally engaged by a coupling member 204 on distal grip 142. Relative movement of the grips 142, 144 towards one another causes the coupling member 204 to pull the return member downwardly with the proximal grip 144 as indicated by arrows. Downward movement of the mandrel 196 causes its retaining ring 200 and spring stop 202 to bear downwardly against the compression spring 198, thereby providing a movement which acts to rotate the grips 142, 144 away from one another. When tension against the grips 142, 144 is released (assuming that heel 188 is not locked into engagement with spring member 190) the grips rotate apart into the opened position as the compression spring 198 returns to the initial state, stowing the applicator head inside the sheath.
The second spring assembly for controlling array deployment is designed to control separation of the flexures. It includes a frame member 178 disposed over yoke 168, Which is pivotally attached to proximal grip 144. Tubing 108 extends from the array 102a (see
A spring stop 172 is fixed to a section of the hypotube within the window 206, and a compression spring 170 is disposed around the hypotube between the spring stop 172 and yoke 168. See
When the distal and proximal grips are moved towards one another, the relative rearward motion of the distal grip causes the distal grip to withdraw the sheath 104 from the array 102a. Referring to
Referring to
In preparation for ablating the uterus utilizing the second exemplary embodiment, the user measures the uterine length using a uterine sound device. The user next positions sliding collar 184 (
Next, with the grips 142, 144 in their resting positions to keep the applicator head 102 covered by sheath 104, the distal end of the device 100 is inserted into the uterus. Once the distal end of the sheath 104 is within the uterus, grips 142, 144 are squeezed together to deploy the applicator head 102 from sheath 104. Grips 142, 144 are squeezed until heel 188 engages with locking spring member 190 as described with respect to
At this point, deflecting mechanism 102b has deployed the array 102a into contact with the uterine walls. The user reads the uterine width, which as described above is transduced from the separation of the spring flexures, from gauge 146. The measured length and width are entered into the RF generator system 250 (
Vacuum source 252 (
Ablation power is supplied to the electrode array 102a by the RF generator system 250. The tissue is heated as the RF energy passes from electrodes 118a-d to the tissue, causing moisture to be released from the tissue. The vacuum source 252 helps to draw moisture from the uterine cavity into the hypotube 122. Moisture withdrawal is facilitated by the apertures 126 formed in flexures 124 by preventing moisture from being trapped between the flexures 124 and the lateral walls of the uterus.
If the RF generator 250 includes an impedance monitoring module, impedance may be monitored at the electrodes 118a-d and the generator may be programmed to terminate RF delivery automatically once the impedance rises to a certain level. The generator system may also or alternatively display the measured impedance and allow the user to terminate RF delivery when desired.
When RF delivery is terminated, the user depresses release lever 194 to disengage heel 188 from locking spring member 190 and to thereby allow grips 142, 144 to move to their expanded (resting) condition. Release of grips 142, 144 causes applicator head 102 to retract to its unexpanded condition and further causes applicator head 102 to be withdrawn into the sheath 104. Finally, the distal end of the device 100 is withdrawn from the uterus.
Two embodiments of ablation devices in accordance with the present invention have been described herein. These embodiments have been shown for illustrative purposes only. It should be understood, however, that the invention is not intended to be limited to the specifics of the illustrated embodiments but is defined only in terms of the following claims.
This application is a continuation of U.S. application Ser. No. 10/959,771 filed Oct. 6, 2004, now U.S. Pat. No. 7,604,633, which is a divisional of U.S. application Ser. No. 09/103,072 filed Jun. 23, 1998, now U.S. Pat. No. 6,813,520, which is a continuation-in-part of U.S. application Ser. No. 08/632,516 filed Apr. 12, 1996, now U.S. Pat. No. 5,769,880, and claims the benefit of U.S. provisional application 60/084,791 filed May 8, 1998.
Number | Name | Date | Kind |
---|---|---|---|
552832 | Fort | Jan 1896 | A |
725731 | Linn | Apr 1903 | A |
1620929 | Wallerich | Mar 1927 | A |
1827306 | Chapman et al. | Oct 1931 | A |
2190383 | Newman | Feb 1940 | A |
2347195 | Huff | Apr 1944 | A |
2466042 | Reich et al. | Apr 1949 | A |
3228398 | Leonard et al. | Jan 1966 | A |
3324855 | Heimlich | Jun 1967 | A |
3645265 | Majzlin | Feb 1972 | A |
3840016 | Lindemann | Oct 1974 | A |
3845771 | Vise | Nov 1974 | A |
3858586 | Lessen | Jan 1975 | A |
3877464 | Vermes | Apr 1975 | A |
3924628 | Droegemueller et al. | Dec 1975 | A |
3948270 | Hasson | Apr 1976 | A |
3967625 | Yoon | Jul 1976 | A |
3971378 | Krantz | Jul 1976 | A |
4022215 | Benson | May 1977 | A |
4057063 | Gieles et al. | Nov 1977 | A |
4082096 | Benson | Apr 1978 | A |
4094320 | Newton et al. | Jun 1978 | A |
4158050 | Zipper | Jun 1979 | A |
4185618 | Corey | Jan 1980 | A |
4233025 | Larson et al. | Nov 1980 | A |
4347842 | Beale | Sep 1982 | A |
4359454 | Hoffman | Nov 1982 | A |
4380238 | Colucci et al. | Apr 1983 | A |
4415288 | Gordon et al. | Nov 1983 | A |
4449528 | Auth et al. | May 1984 | A |
4465072 | Taheri | Aug 1984 | A |
4492231 | Auth | Jan 1985 | A |
4532483 | Schminke | Jul 1985 | A |
4532924 | Auth et al. | Aug 1985 | A |
4568326 | Rangaswamy | Feb 1986 | A |
4582057 | Auth et al. | Apr 1986 | A |
4601698 | Moulding, Jr. | Jul 1986 | A |
4606336 | Zeluff | Aug 1986 | A |
4628924 | Cimber | Dec 1986 | A |
4662383 | Sogawa et al. | May 1987 | A |
4676258 | Inokuchi et al. | Jun 1987 | A |
4691703 | Auth et al. | Sep 1987 | A |
4700701 | Montaldi | Oct 1987 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
4765331 | Petruzzi et al. | Aug 1988 | A |
4788966 | Yoon | Dec 1988 | A |
4807620 | Strul et al. | Feb 1989 | A |
4832048 | Cohen | May 1989 | A |
4865047 | Chou et al. | Sep 1989 | A |
4869268 | Yoon | Sep 1989 | A |
4946440 | Hall | Aug 1990 | A |
4949718 | Neuwirth et al. | Aug 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4960133 | Hewson | Oct 1990 | A |
4961435 | Kitagawa et al. | Oct 1990 | A |
4979948 | Geddes et al. | Dec 1990 | A |
4981465 | Ballan et al. | Jan 1991 | A |
4983177 | Wolf | Jan 1991 | A |
5026379 | Yoon | Jun 1991 | A |
5047028 | Qian | Sep 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5065751 | Wolf | Nov 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5105808 | Neuwirth et al. | Apr 1992 | A |
5147353 | Everett | Sep 1992 | A |
5159925 | Neuwirth et al. | Nov 1992 | A |
5160334 | Billings et al. | Nov 1992 | A |
5178148 | Lacoste et al. | Jan 1993 | A |
5186181 | Franconi et al. | Feb 1993 | A |
5188122 | Phipps et al. | Feb 1993 | A |
5188602 | Nichols | Feb 1993 | A |
5217473 | Yoon | Jun 1993 | A |
5226908 | Yoon | Jul 1993 | A |
5242437 | Everett et al. | Sep 1993 | A |
5248312 | Langberg | Sep 1993 | A |
5263585 | Lawhon et al. | Nov 1993 | A |
5277201 | Stern | Jan 1994 | A |
5308327 | Heaven et al. | May 1994 | A |
5318532 | Frassica | Jun 1994 | A |
5322507 | Costello et al. | Jun 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5334209 | Yoon | Aug 1994 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5357956 | Nardella | Oct 1994 | A |
5364393 | Auth et al. | Nov 1994 | A |
5370649 | Gardetto et al. | Dec 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5374283 | Flick | Dec 1994 | A |
5380317 | Everett et al. | Jan 1995 | A |
5383917 | Desai et al. | Jan 1995 | A |
5385544 | Edwards et al. | Jan 1995 | A |
5395311 | Andrews | Mar 1995 | A |
5405322 | Lennox et al. | Apr 1995 | A |
5407071 | Lawhon et al. | Apr 1995 | A |
5423808 | Edwards et al. | Jun 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5437629 | Goldrath | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5451204 | Yoon | Sep 1995 | A |
5474089 | Waynant | Dec 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5498261 | Strul | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5514091 | Yoon | May 1996 | A |
5540655 | Edwards et al. | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5542916 | Hirsch et al. | Aug 1996 | A |
5558672 | Edwards et al. | Sep 1996 | A |
5562703 | Desai | Oct 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5573533 | Strul | Nov 1996 | A |
5575788 | Baker et al. | Nov 1996 | A |
5588961 | Leone et al. | Dec 1996 | A |
5593404 | Costello et al. | Jan 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5599346 | Edwards et al. | Feb 1997 | A |
5609598 | Laufer et al. | Mar 1997 | A |
5613950 | Yoon | Mar 1997 | A |
5620481 | Desai et al. | Apr 1997 | A |
5649924 | Everett et al. | Jul 1997 | A |
5656013 | Yoon | Aug 1997 | A |
5658316 | Lamond et al. | Aug 1997 | A |
5667520 | Bonutti | Sep 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5716343 | Kriesel et al. | Feb 1998 | A |
5722975 | Edwards et al. | Mar 1998 | A |
5730136 | Laufer et al. | Mar 1998 | A |
5730725 | Yoon | Mar 1998 | A |
5733252 | Yoon | Mar 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5807389 | Gardetto et al. | Sep 1998 | A |
5810847 | Laufer et al. | Sep 1998 | A |
5827273 | Edwards | Oct 1998 | A |
5843026 | Edwards et al. | Dec 1998 | A |
5843121 | Yoon | Dec 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5865788 | Edwards et al. | Feb 1999 | A |
5871469 | Eggers et al. | Feb 1999 | A |
5879348 | Owens et al. | Mar 1999 | A |
5885601 | Sokal | Mar 1999 | A |
5888198 | Eggers et al. | Mar 1999 | A |
5891134 | Goble et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5897551 | Everett et al. | Apr 1999 | A |
5897553 | Mulier et al. | Apr 1999 | A |
5935123 | Edwards et al. | Aug 1999 | A |
5935137 | Saadat et al. | Aug 1999 | A |
5938660 | Swartz et al. | Aug 1999 | A |
5944715 | Goble et al. | Aug 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
5979446 | Loy | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
6002968 | Edwards | Dec 1999 | A |
6014589 | Farley et al. | Jan 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6041260 | Stern et al. | Mar 2000 | A |
6042596 | Bonutti | Mar 2000 | A |
6047700 | Eggers et al. | Apr 2000 | A |
6066139 | Ryan et al. | May 2000 | A |
6068613 | Kriesel et al. | May 2000 | A |
6068626 | Harrington et al. | May 2000 | A |
6071277 | Farley et al. | Jun 2000 | A |
6074386 | Goble et al. | Jun 2000 | A |
6077257 | Edwards et al. | Jun 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6135997 | Laufer et al. | Oct 2000 | A |
6139527 | Laufer et al. | Oct 2000 | A |
6139546 | Koenig et al. | Oct 2000 | A |
6152899 | Farley et al. | Nov 2000 | A |
6159207 | Yoon | Dec 2000 | A |
6164280 | Everett et al. | Dec 2000 | A |
6165172 | Farley et al. | Dec 2000 | A |
6179832 | Jones et al. | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6193713 | Geistert et al. | Feb 2001 | B1 |
6197025 | Grossi et al. | Mar 2001 | B1 |
6200312 | Zikorus et al. | Mar 2001 | B1 |
6231496 | Wilk et al. | May 2001 | B1 |
6231507 | Zikorus et al. | May 2001 | B1 |
6234178 | Goble et al. | May 2001 | B1 |
6237606 | Zikorus et al. | May 2001 | B1 |
6238393 | Mulier et al. | May 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6245090 | Gilson et al. | Jun 2001 | B1 |
6254601 | Burbank et al. | Jul 2001 | B1 |
6258084 | Goldman et al. | Jul 2001 | B1 |
6258085 | Eggleston | Jul 2001 | B1 |
6263248 | Farley et al. | Jul 2001 | B1 |
6277089 | Yoon | Aug 2001 | B1 |
6293942 | Goble et al. | Sep 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6309384 | Harrington et al. | Oct 2001 | B1 |
6315776 | Edwards et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6346102 | Harrington et al. | Feb 2002 | B1 |
6352549 | Everett | Mar 2002 | B1 |
6364877 | Goble et al. | Apr 2002 | B1 |
6369465 | Swanson | Apr 2002 | B1 |
6395012 | Yoon et al. | May 2002 | B1 |
6398780 | Farley et al. | Jun 2002 | B1 |
6402742 | Blewett et al. | Jun 2002 | B1 |
6428537 | Swanson et al. | Aug 2002 | B1 |
6432116 | Callister et al. | Aug 2002 | B1 |
6451015 | Rittman, III et al. | Sep 2002 | B1 |
6475213 | Whayne et al. | Nov 2002 | B1 |
6485487 | Sherman | Nov 2002 | B1 |
6485500 | Kokish et al. | Nov 2002 | B1 |
6490474 | Willis et al. | Dec 2002 | B1 |
6508815 | Strul et al. | Jan 2003 | B1 |
6554780 | Sampson et al. | Apr 2003 | B1 |
6663626 | Truckai et al. | Dec 2003 | B2 |
6679269 | Swanson | Jan 2004 | B2 |
6712810 | Harrington et al. | Mar 2004 | B2 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6726682 | Harrington et al. | Apr 2004 | B2 |
6743184 | Sampson et al. | Jun 2004 | B2 |
6764488 | Burbank et al. | Jul 2004 | B1 |
6813520 | Truckai et al. | Nov 2004 | B2 |
6964274 | Ryan et al. | Nov 2005 | B1 |
7074217 | Strul et al. | Jul 2006 | B2 |
7407502 | Strul et al. | Aug 2008 | B2 |
7512445 | Truckai et al. | Mar 2009 | B2 |
7604633 | Truckai et al. | Oct 2009 | B2 |
7717909 | Strul et al. | May 2010 | B2 |
7731712 | Sampson et al. | Jun 2010 | B2 |
7846160 | Payne et al. | Dec 2010 | B2 |
20010041900 | Callister et al. | Nov 2001 | A1 |
20020022870 | Truckai et al. | Feb 2002 | A1 |
20020029051 | Callister et al. | Mar 2002 | A1 |
20020072499 | Clagett | Jun 2002 | A1 |
20020072745 | Truckai et al. | Jun 2002 | A1 |
20020177846 | Mulier et al. | Nov 2002 | A1 |
20030093101 | O'Heeron et al. | May 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20040054368 | Truckai et al. | Mar 2004 | A1 |
20040118166 | Huang et al. | Jun 2004 | A1 |
20040172051 | Ravikumar | Sep 2004 | A1 |
20040204720 | Harrington et al. | Oct 2004 | A1 |
20040255958 | Harrington et al. | Dec 2004 | A1 |
20050085880 | Truckai et al. | Apr 2005 | A1 |
20050155608 | Pavcnik et al. | Jul 2005 | A1 |
20050217680 | Callister et al. | Oct 2005 | A1 |
20060135956 | Sampson et al. | Jun 2006 | A1 |
20080071269 | Hilario et al. | Mar 2008 | A1 |
20100036372 | Truckai et al. | Feb 2010 | A1 |
20100217256 | Strul et al. | Aug 2010 | A1 |
20120179155 | Strul et al. | Jul 2012 | A1 |
Number | Date | Country |
---|---|---|
384246 | Oct 1923 | DE |
22 22 820 | Nov 1973 | DE |
40 01 086 | Jul 1991 | DE |
0 056 178 | Apr 1981 | EP |
0 584 930 | Jul 1993 | EP |
1 400 182 | Mar 2004 | EP |
1 568 325 | Aug 2005 | EP |
774 550 | Dec 1934 | FR |
2 115 706 | Jul 1972 | FR |
2 317 566 | Apr 1998 | GB |
48-67586 | Dec 1971 | JP |
58-32756 | Feb 1983 | JP |
63-318934 | Dec 1988 | JP |
9219145 | Nov 1992 | WO |
9400178 | Jan 1994 | WO |
9407445 | Apr 1994 | WO |
9410948 | May 1994 | WO |
9423794 | Oct 1994 | WO |
9504385 | Feb 1995 | WO |
9505869 | Mar 1995 | WO |
9507664 | Mar 1995 | WO |
9510326 | Apr 1995 | WO |
9600042 | Jan 1996 | WO |
9712569 | Apr 1997 | WO |
9741785 | Nov 1997 | WO |
9838932 | Sep 1998 | WO |
9958070 | Nov 1999 | WO |
0197897 | Dec 2001 | WO |
Entry |
---|
“Essure, Permanent Birth Control by Conceptus: What is Essure?” Product Information Sheet [on-line] [retrieved Oct. 19, 2004] Retrieved from the Internet: < URL: http://www.essure.com/consumer/c.sub.--what.sub.--is.sub.--essure.aspx >. |
“Essure: the non-incisional approach to permanent birth control”, Patient Information Booklet, .COPYRGT. 2004 by Conceptus Incorporated. |
“Tubal Ligation and Resection: Tubal Ligation by Parkland and Irving Methods” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--resection.htm >. |
“Tubal Ligation Methods: Coagulation Methods of Tubal Ligation” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004, [retrieved Oct. 19, 2004] Retrieved from the Internet: < http://www.tubal-reversal.net/tubal.sub.--ligation.sub.--coagulation.htm >. |
“Tubal Ligation—Fimbriectomy: Tubal Reversal is Possible after Fimbriectomy” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--fimbriectomy.htm >. |
“Tubal Ligation—Pomeroy Technique: Pomeroy Tubal Ligation and Resection” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004 ] Retrieved from the Internet: < http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--Pomeroy.htm >. |
“Tubal Ligation—Tubal Ring or Clip: Tubal Ligation with Tubal Rings or Tubal Clips” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/tubal.sub.--ligation-tubal.sub.--ring-tubal- .sub.--clip.htm >. |
Adiana options for women—how it works. (Dec. 31, 2005). Retrieved from http://web.archive.org/web/20051124001429/www.adiana.com/products.sub.--h- ow.php. |
C. Nibley et al., “Prevention of Impedance Rise During Radiofrequency Current Catheter Ablation by Intra-Electrode Tip Chilling,” Circulation [Abstracts From the 67th Scientific Sessions, Dallas Convention Center, Dallas, Texas, Nov. 14-17, 1994], vol. 90, No. 4, Part 2, Oct. 1994, p. 460. |
D.E. Haines et al., “Observations on Electrode-Tissue Interface Temperature and Effect on Electrical Impedance During Radiofrequency Ablation of Ventricular Myocardium,” Circulation, vol. 82, No. 3, Sep. 1990, pp. 1034-1038. |
METI-MyriadLase, SteriLase, Powerpoint Presentation, published at least as of Jun. 13, 2006, 6 pp. |
W.M. Jackman et al., “Radiofrequency Current Directed Across the Mitral Anulus With a Bipolar Epicardial-Endocardial Catheter Electrode Configuration in Dogs,” Circulation, vol. 78, No. 5, Nov. 1988, pp. 1288-1298. |
First Request for Ex Partes Reexamination of U.S. Patent No. 5,769,880, filed Jul. 27, 1999, U.S. Appl. No. 90/005,435. |
Second Request for Ex Partes Reexamination of U.S. Patent No. 5,769,880, filed Nov. 22, 2000, U.S. Appl. No. 90/005,866. |
Number | Date | Country | |
---|---|---|---|
20100036372 A1 | Feb 2010 | US | |
20130165913 A9 | Jun 2013 | US |
Number | Date | Country | |
---|---|---|---|
60084791 | May 1998 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09103072 | Jun 1998 | US |
Child | 10959771 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10959771 | Oct 2004 | US |
Child | 12581506 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 08632516 | Apr 1996 | US |
Child | 09103072 | US |